Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
SCOTTA.ARMSTRONG,M.D.,Ph.D. Chair,DepartmentofPediatricOncology,Dana-FarberCancerInstitute Dr.Armstrongisapediatriconcologistandleaderinleukemiaresearchwhose studieshaveledtoseveralfindingsthatpointtopromisingnewtherapies.Among Dr.Armstrong’smostnotableachievementswastheidentificationofrareleukemia stemcellsinMLL-rearrangedleukemias,alethalformofleukemiathatisfoundin childrenandadults.Inrelatedwork,Dr.Armstrong’sgrouphasbeenstudyingthe roleofhistonemodificationsandchromosomestructureasacriticalinitialstepin leukemiadevelopment,whichhaspromptedasearchfortherapiesthatcanreverse thisprocessanderadicateleukemiacells.Thisworkledtothedevelopmentofnew therapiesthatarenowbeingtestedinpatients. Dr.ArmstrongreceivedhisMDandPhDfromtheUniversityofTexasSouthwestern MedicalSchoolinDallas,Texas.Heperformedhisresidencyandfellowshipin pediatrichematology/oncologyatChildren’sHospitalBoston,theDanaFarber CancerInstitute,andHarvardMedicalSchool.Dr.Armstronghasbeenawardedthe TillandMcCullochAwardfromtheInternationalSocietyofExperimental Hematology,thePaulMarksPrizeforCancerResearchfromMemorialSloan KetteringCancerCenter,theE.MeadJohnsonAwardforOutstandingResearchin PediatricsandtheDameshekPrizefromtheAmericanSocietyofHematology. BRADLEYE.BERNSTEIN,M.D.,Ph.D. ProfessorofPathology,MassachusettsGeneralHospital BradleyBernsteinistheBernardandMildredKaydenResearchInstituteChairanda ProfessorofPathologyatMassachusettsGeneralHospital,aBroadInstitute Member,andanAmericanCancerSocietyResearchProfessor.Bernstein’sresearch focusesonepigenetics—changesingeneactivitygovernedbyinfluencesoutside thegenesthemselves—andspecificallyhowmodificationstotheproteinscaffold calledchromatincontributetomammaliandevelopmentandhumancancer. BernsteinreceivedhisB.S.fromYaleUniversityandhisM.D.andPh.D.fromthe UniversityofWashington,beforecompletingaresidencyinclinicalpathologyand postdoctoralresearchatHarvardUniversity.HonorsincludethePaulMarksPrize forCancerResearch,anEarlyCareerScientistawardfromtheHowardHughes MedicalInstitute,andaCareerAwardintheBiomedicalSciencesfromthe BurroughsWellcomeFund. JAMESE.BRADNER,M.D. President,NovartisInstitutesforBioMedicalResearch PriortojoiningNovartisDr.BradnerservedontheresearchfacultyofHarvard MedicalSchoolandasanattendingphysicianinstemcelltransplantationwithinthe DepartmentofMedicalOncologyattheDana-FarberCancerInstitute.Theresearch focusoftheBradnerlaboratoryhasbeenthestudyofBETbromodomainproteins andtheirfunctioningenecontrol,innovatingchemicalprobesandinvestigational drugstostudyandtreatcancer.Dr.Bradnerisaco-founderoffivebiotechnology companiesandhasco-authoredmorethan150scientificpublicationsand30United Statespatentapplications. Dr.BradnerisagraduateofHarvardCollegeandtheUniversityofChicagoPritzker SchoolofMedicine.HecompletedresidencyinMedicineatBrigham&Women's Hospital,fellowshipsinMedicalOncologyandHematologyattheDana-Farber CancerInstituteandpostdoctoraltraininginChemistryandChemicalBiologyat HarvardUniversity(Prof.StuartSchreiber).Heistherecipientofmanyhonorific awardsandwaselectedintotheAmericanSocietyofClinicalInvestigationin2011 andtheAlphaOmegaAlphaHonorMedicalSocietyin2013. ROBERTA.COPELAND,Ph.D. President,ResearchandChiefScientificOfficer,Epizyme,Inc. RobertA.Copeland,Ph.D.isPresidentofResearchandChiefScientificOfficerat Epizyme,Inc.HejoinedEpizymeinSeptember2008,fromGlaxoSmithKline,where hewasVicePresidentofCancerBiology,OncologyCenterofExcellenceinDrug Discovery.Dr.Copelandhasalsoservedonanumberofadvisoryboards, committeesandeditorialboardsinindustry,academia,professionalsocietiesand professionaljournals.BeforejoiningGSKheheldscientificstaffpositionsatMerck ResearchLaboratories,DuPont-MerckandBristol-MyersSquibbandafaculty positionattheUniversityofChicago,PritzkerSchoolofMedicine.Dr.Copeland receivedhisB.S.inchemistryfromSetonHallUniversity,hisdoctorateinchemistry fromPrincetonUniversityanddidpostdoctoralstudiesastheChaimWeizmann FellowattheCaliforniaInstituteofTechnology. Hisresearchinterestisinelucidatingthedeterminantsofdrugrecognitionbytheir biologicaltargets,andtheuseofthisinformationinthediscoveryanddesignofnew medicines.Acommonthemethroughouthisresearchhasbeentheroleofprotein dynamicsindrug-targetinteractions.In2006Dr.Copelandformulatedthedrugtargetresidencetimemodel,anovel,alternativeapproachtodrugoptimizationthat hasbeenwidelyadoptedthroughoutthebiotechnologyandpharmaceutical industries.Hehascontributedtodrugdiscoveryanddevelopmenteffortsacross multipletherapeuticareas,leadingto18drugcandidatesenteringhumanclinical trials.Theseincludethecancerdrugsforetinib,afuresertib,pinometostat, tazemetostat,Tafinlar(dabrafenib)andMekinist(trametinib)andtheantibiotic Altabax(retapamulin).Dr.Copelandhascontributedmorethan200publicationsto thescientificliterature,holds13issuedU.S.patentsandhasauthored5booksinthe areasofproteinscienceandenzymology. Hismostrecentbook,EvaluationofEnzymeInhibitorsinDrugDiscovery:AGuide forMedicinalChemistsandPharmacologists,2ndEdition(Wiley,Hoboken,NJ), publishedinMarch2013. LISADREW,Ph.D. Director,OncologyBioscience,AstraZenecaR&DBoston LisaDrewisDirectorofOncologyBioscienceatAstraZenecaR&DBostonlocatedin Waltham,MA.Duringher16yearsworkingatAstraZeneca,DrDrewhasledthe progressionanddeliveryofmultipleoncologydrugdiscoveryprogramsfocusedon targetingkinasesdrivingkeysignalingpathways,includingBRAF,CSF1RandALKas thescientificleaderfromhitidentificationtocandidatedrugnomination.Currently, sheisinvolvedinleadingthecelldeathstrategyforOncologyatAstraZenecaand overseesthebiologyformultipleprogramsasateamleader.Lisaactively participatesintheAstraZenecapostdoctoralprogramastheOncology representativeaswellasthegraduateinternprogram.ShereceivedherBScin BiologyandPhDincancercellbiologyfromUniversityofYork,Englandanddid postdoctoraltrainingatUniversityofCalifornia,IrvineandColumbiaUniversity, NewYorkbeforejoiningAstraZeneca. RONALDM.EVANS,Ph.D. ProfessorandDirectorGeneExpressionLaboratory,SalkInstituteforBiological Studies ProfessorEvansisDirectoroftheGeneExpressionLaboratoryandMetabolic EngineeringProgramandCo-DirectoroftheHelmsleyCenterforGenomic Medicine.Heisknownforpioneeringstudiesonhormonesignalinginphysiology andindisease.HisdiscoveryoftheNuclearReceptorSuperfamilyprovidedaunified signalingmechanismforsteroids,vitaminA,vitaminD,thyroidhormonesandbile acids.Thesereceptorsusetranscriptiontocontrolsugar,salt,calcium,cholesterol andfatmetabolism.Theyareprimarytargetsinbreast,prostateandpancreatic cancers,andleukemiatreatment,andhavetherapeuticrolesinchronic inflammation,osteoporosisandasthma.Hisworkonmusclemetabolismledtothe discoveryof‘exercisemimetics,’whichpromotethebenefitsoffitnesswithout training.Exercisemimeticswillhelpbattletheobesityepidemic,diabetes,heart disease,hypertensionandcancer.HisworkonVitaminDuncoveredahidden mechanismtoreprogrampancreaticcancerandincreaseitsresponseto chemotherapy.HeisaHowardHughesMedicalInstituteInvestigatorandthe recipientofmultipleawards,includingtheAlbertLaskerAward(2004)andthe WolfPrize(2012),andisaMemberoftheNationalAcademyofSciencesandthe InstituteofMedicine. STEPHENFRYE,Ph.D. Director,CenterforIntegrativeChemicalBiologyandDrugDiscovery,Universityof NorthCarolinainChapelHill AsdirectoroftheCenterforIntegrativeChemicalBiologyandDrugDiscoveryat UNC,Dr.Fryeplaysakeyroleintranslationalresearchthroughcollaborativedrug discoveryprojectswithotherUNCfaculty.Inaddition,hisCenterhasinitiateda programintheareaofchemicalbiologyofchromatinregulation.Dr.Fryehasa broadbackgroundindrugdiscoveryanddevelopmenthavingco-discovereda marketedproducthimself(Avodart)andcreatedadepartmentthatdiscoveredtwo FDAapprovedkinaseinhibitoroncologytherapies(LapatinibandPazopanib)while atGSK.SincejoiningUNCin2007,Dr.Frye’sCenterhasbeendesignatedasoneof theNationalCancerInstitute’schemicalbiologycenters.Dr.FryereceivedhisPh.D. inorganicchemistryfromUNCChapelHillunderthementorshipofthelateProf. ErnestEliel.Heistheauthorofover100patentsandpublications. NATHANAELS.GRAY,Ph.D. Professor,BiologicalChemistryandMolecularPharmacology,HarvardMedical School NathanaelGrayspenthischildhoodinZambia,Yemen,IndiaandSudanbefore returningtotheUStoattendhighschoolatBerkeleyHighinCalifornia.Nathanael GrayreceivedhisPhDinorganicchemistryfromtheUniversityofCaliforniaat Berkeleyin1999wherehediscoveredPurvalanol,oneofthefirstselective inhibitorsofcyclin-dependentkinases.HethenmovedtotheGenomicsInstituteof theNovartisResearchFoundationinSanDiego,whereafterservingasastaff scientistandgroupleaderofkinaseinhibitorchemistry,hewasnameddirectorof biologicalchemistryin2001.Dr.Gray’sresearchteamwasresponsibleforthe developmentofseveralclinicalcandidates,includingBAF312whichiscurrently undergoingphaseIIIclinicaltrialsforthetreatmentofMultipleSclerosis.Dr.Gray joinedthefacultyofHarvardMedicalSchoolandtheDanaFarberCancerInstitutein 2006tocontinuehisresearchusingsyntheticchemistryandfunctionalsmall moleculediscoverytomodulatebiologicalpathwaysimportantincancer.His researchgrouphasbeenresponsibleforthediscoveryofnovelinhibitorsofwildtypeandmutantformsofEGFR(WZ4002),mTor(Torin1andTorin2),Bcr-Abl (GNF-2,GNF-5,HG-7-85-01),Mps1(Mps1-IN-1Mps1-IN-2),Erk5(XMD8-92),b-Raf, LRRK2(LRRK2-IN-1),Jnk1,2,3(JNK-IN-7)andEphrinkinaseswhichhavebecome widelyusedresearchtoolsandhaveinspiredseveraldrugdiscoveryprograms. CIGALLKADOCH,Ph.D. AssistantProfessor,PediatricOncology,HarvardMedicalSchool CigallKadochisanAssistantProfessorofPediatricOncologyattheDana-Farber CancerInstituteandHarvardMedicalSchoolandanInstituteMemberoftheBroad InstituteofMITandHarvard.Dr.Kadochstudieschromatinregulation,withstrong focusonthestructureandfunctionofthemammalianSWI/SNForBAFfamilyof chromatinremodelingcomplexesinhumancancer.Herworkhasbeencenteredin mechanisticallyinterrogatingrare,molecularlywell-definedcancers,tounderstand therolethesecomplexesplayinpromotingawiderangeofmorecommoncancer types. KadochcompletedhergraduateandpostdoctoralresearchattheStanford UniversitySchoolofMedicine.Workingalongsiderenowneddevelopmental biologistGeraldCrabtree,sheusedaseriesofbiochemicalexperimentstoidentifya novelsetofproteins,componentsofthemSWI/SNForBAFcomplex,whichregulate chromatinstructure.Uponthesediscoveries,Kadochandhercolleaguesthenlinked mutationsinthesubunitsofBAFcomplexestomorethanone-fifthofhuman cancers.Inaddition,sheworkedtouncovertheprecisemechanismofBAFcomplex perturbationinarare,aggressivesoft-tissuesarcoma,knownassynovialsarcoma. Kadochisnowdevelopingnewapproachestothestructuralandfunctional interrogationofchromatinregulatorsanddevelopingtherapeuticapproachesfor cancersdrivenbyBAFmutations. KadochearnedherundergraduatedegreeinMolecularandCellBiologyfromthe UniversityofCalifornia,Berkeley,andherPh.D.inCancerBiologyfromtheStanford UniversitySchoolofMedicine.In2014,shortlybeforebecomingoneoftheyoungest AssistantProfessorsappointedtothefacultyofHarvardMedicalSchool,shewas namedtoForbesMagazine’s30Under30inScience&Healthcare,andin2015,the MITTechnologyReviewTopInnovatorsUnder35.Sheisalsotherecipientofthe NIHDirector’sNewInnovatorAwardandwasrecentlynamedaPew-Stewart ScholarinCancerResearch. ANGELAKOEHLER,Ph.D. AssistantProfessor,DepartmentofBiologicalEngineering,MIT AngelaKoehleristheKarlVanTasselAssistantProfessorintheDepartmentof BiologicalEngineeringatMITandanintramuralmemberoftheDavidH.Koch InstituteforIntegrativeCancerResearchatMIT.SheisalsoanAssociateMemberof theBroadInstitute.Herresearchgroupaimstodiscoveranddevelopfunctional small-moleculeprobesoftranscriptionalregulators,includingchromatinmodifying enzymesandoncogenictranscriptionfactors.Validatedprobesmaybeusedto advancetheunderstandingoftranscriptionindevelopmentanddisease.Selected probesmaybedevelopedintoimagingagents,diagnostictools,ortherapeuticleads. AngelareceivedherB.A.inBiochemistryandMolecularBiologyfromReedCollege in1997.In2003,shereceivedherPh.D.inChemistryfromHarvardUniversity.Upon graduation,shebecameanInstituteFellowintheChemicalBiologyProgramatthe BroadInstituteandaGroupLeaderfortheNCIInitiativeforChemicalGenetics.She servesasFacultyCo-DirectoroftheHigh-ThroughputSciencesFacilityinthe SwansonBiotechnologyCenterattheKochInstituteandservesontheChemistsin CancerResearchsteeringcommitteefortheAmericanAssociationforCancer Research.HonorsincludebeingnamedaGenomeTechnologyYoungInvestigator andaMerkinInstituteFellow. ROSSL.LEVINE,M.D. Director,MemorialSloanKetteringCenterforHematologicMalignancies RossLevine,MD,isaMemberoftheHumanOncologyandPathogenesisProgram andanAttendingPhysicianontheLeukemiaService,DepartmentofMedicineandis theLaurenceJosephDineenChairinLeukemiaResearchandthedirectoroftheMSK CenterforHematologicMalignancies.Dr.LevinereceivedhisABfromHarvard CollegeandaM.D.fromJohnsHopkins.Dr.LevineservedasanResidentinInternal MedicineattheMGHandsubsequentlyasaHematology-OncologyFellowatDFCI. HethenjoinedGaryGilliland’slaboratoryasapostdoctoralfellowandperformed kinomesequencingattheBroadInstitutetoidentifyJAK2V617FandMPLmutations inMPNpatients.InSeptember2007hewasrecruitedtoMSKtotheHuman OncologyandPathogenesisProgramwhileheseespatientsontheLeukemia Service.Hislabinvestigatestheroleofsomaticmutationsinsignalingeffectorsand inepigeneticmodifiersinMPNandinAML. ERICR.OLSON,Ph.D. ChiefScientificOfficer,SyrosPharmaceuticals Erichas30yearsofexperienceinthebiopharmaindustry.PriortojoiningSyros Pharmaceuticalsin2013,heheldseveralseniorpositionsatVertexPharmaceuticals inresearch,developmentandcommercializationofcysticfibrosis(CF)drugsbased onthe1989discoveryoftheCFgene.Duringthistimeheleddevelopmentteams forKalydecoandOrkambiandservedastheCFfranchisehead.Inadditiontohis workatVertex,Dr.Olsonheldpositionsininfectiousdiseasesandgeneexpression atUpjohnandWarner-Lambert/Pfizer.Dr.OlsonearnedhisB.S.inMicrobiology fromtheUniversityMinnesotaandaPh.D.inMicrobiologyandImmunologyfrom theUniversityofMichigan. MATTHEWSHAIR,Ph.D. Professor,DepartmentofChemistryandChemicalBiology,HarvardUniversity MatthewShairisaProfessorintheDepartmentofChemistryandChemicalBiology atHarvardUniversity,anassociateoftheBroadInstituteandanaffiliateofthe HarvardStemCellInstitute.Hislabstudiesthemechanisticbasisofhumandiseases, identifiesnewtargets,anddevelopssmallmoleculetherapeutics.Hislaboratoryhas discoveredthatinhibitionofCDK8andCDK19isanewtherapeuticapproachto acutemyeloidleukemia(AML)involvingunanticipatedeffectsontranscriptionof cellidentitygenes.Hehasalsousedsmallmoleculestodiscoverthatoxysterolbindingproteinsareadruggabledependencyofsolidtumorcells.Hislabisknown fortheircreativesynthesisofcomplexnaturallyoccurringmolecules.Hehasbeen therecipientofseveralawardsforhiswork,mostnotablytheRaymondandBeverly SacklerPrizeinthePhysicalSciences-ChemistryadministeredbyTelAviv UniversityandtheArthurC.CopeScholarAward.Hehasbeenafounderofseveral biotechcompaniesincludingInfinityPharmaceuticals(Nasdaq:INFI),MakotoLife SciencesandChemiderm.HehasalsobeenanadvisortoAriad,Enanta,BristolMyersSquibbandNovartis.Moleculescreatedinhislabforthetreatmentofcancer havebeenlicensedbyMerckinoneofthelargestlicensingdealsofanacademic preclinicalasset. KIMBERLYSTEGMAIER,M.D. AssociateProfessor,Pediatrics,HarvardMedicalSchool KimberlyStegmaier,anAssociateProfessorofPediatricsatHarvardMedicalSchool andaPrincipalInvestigatoratDana-FarberCancerInstitute(DFCI),hasadvanced theapplicationofgenomicstodrugandproteintargetdiscoveryforpediatric cancers.SheistheViceChairforPediatricOncologyResearchandCo-directorofthe PediatricHematologicMalignancyProgramandanattendingphysicianproviding clinicalcareinPediatricOncologyattheDana-FarberCancerInstituteandBoston Children’sHospital.Dr.StegmaierisalsoanInstituteMemberoftheBroadInstitute ofHarvardandMIT. TheStegmaierlaboratorydevelopsandintegrateschemicalandfunctionalgenomic approachestoidentifynewproteintargetsandsmall-moleculemodulatorsof malignancywithaneyetowardclinicaltranslation.Thelaboratoryhasfocusedon pediatricmalignanciesnotablefortheaberrancyofdifferentiationand/oroncogenic activationoftranscriptionfactors:theacuteleukemias,neuroblastoma,andEwing sarcoma.Multipleclinicaltrialshaveresultedfromherlaboratory’sresearch.Dr. Stegmaierhaswonnumerousawardsforherwork,includingtheSPRYoung InvestigatorAward,theSirWilliamOslerYoungInvestigatorAwardfromthe InterurbanClinicalClub,aSU2CInnovativeResearchGrant,andthe2016E.Mead JohnsonAwardforResearchinPediatrics. Dr.StegmaierwaselectedtotheSocietyforPediatricResearchin2007andthe AmericanSocietyforClinicalInvestigationin2009.Sheisastrongadvocatefor pediatricresearch,servingasaCouncilMemberwiththeSocietyforPediatric Researchfrom2013-2016andaSteeringCommitteeMemberwiththeAACR PediatricCancerWorkingGroupfrom2011-2016.ShewasrecentlyawardedtheA. CliffordBargerExcellenceinMentoringAwardfromHarvardMedicalSchoolforher commitmenttotrainingthenextgenerationofpediatriccancerresearchers. Dr.StegmaierreceivedherundergraduatedegreefromDukeUniversity,medical degreefromHarvardMedicalSchool,andtrainedinPediatricsandPediatric Hematology/OncologyatBostonChildren’sHospitalandtheDana-FarberCancer Institute. RICHARDA.YOUNG,Ph.D. Professor,WhiteheadInstituteandMIT RichardYoungisaProfessorattheWhiteheadInstituteandMIT.Dr.Youngstudies generegulationinhealthanddisease.HehasservedasanadvisortotheWorld HealthOrganization,theNationalInstitutesofHealthandnumerousscientific societiesandjournals.Dr.Young’shonorsincludeMembershipintheNational AcademyofSciencesandScientificAmericanhasrecognizedhimasoneofthetop 50leadersinscience,technologyandbusiness.Hehasfoundedandadvised companiesinthebiotechnologyandpharmaceuticalindustry,andiscurrentlya memberoftheBoardofDirectorsofSyrosPharmaceuticals.Dr.Youngisalsoan aviatorandholdsacommercialpilotlicense.